Nucelion Therapeutics

Nucelion Therapeutics is a biotechnology company focused on the discovery and development of RNA-targeted small molecule (rSM) therapeutics. The company utilizes a proprietary platform to identify small molecules that can bind to and modulate the function of disease-causing RNA structures, effectively expanding the druggable genome beyond proteins. Their research is primarily directed toward high-value indications in oncology, neurology, and rare genetic diseases. Founded by pioneers in RNA-targeting chemistry, Nucelion aims to translate complex RNA biology into transformative medicines for patients with unmet medical needs. The company is currently in the pre-clinical stage, advancing a pipeline of novel candidates designed to target previously "undruggable" RNA sequences.